1032827-78-3

Basic information

• Product Name: (S)-2-((3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione
• Synonyms: (S)-2-((3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione
• CAS NO: 1032827-78-3
• Molecular Weight: 419.207
• Mol File: 1032827-78-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-2-((3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-((3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione(1032827-78-3)
• EPA Substance Registry System: (S)-2-((3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione(1032827-78-3)

Safety Data

• Hazardous Substances Data: 1032827-78-3(Hazardous Substances Data)

Upstream product

• 856676-99-8 methanesulfonic acid (5R)-3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl ester 
• 1074-82-4 potassium phtalimide 
• 656-65-5 3-fluoro-4-bromophenylamine 
• 510729-01-8 (4-bromo-3-fluorophenyl)carbamic acid benzyl ester 
• 444335-16-4 (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxylmethyl)oxazolidin-2-one 
• 161596-47-0 (S)-N-glycidylphthalimide 
• 1032827-77-2 2-((R)-3-(4-bromo-3-fluorophenylamino)-2-hydroxypropyl)isoindolin-1,3-dione 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 856677-03-7 (S)-5-(aminomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one 
• 1032827-88-5 (S)-N-((3-(4-(4-(1,4,5,6-tetrahydro-pyrimidin-2-yl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032897-88-3 (S,Z)-N-((3-(4-(4-(N'-hydroxycarbamimidoyl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032827-87-4 (S)-N-((3-(4-(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032827-83-0 (S)-N-((3-(4-(4-(4,5-dihydro-5,5-dimethyl-1,2,4-oxadiazol-3-yl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032827-86-3 (S,Z)-N-((3-(4-(4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032827-84-1 (S)-N-((3-(4-(4-(5-oxo-1,2,4-oxadiazol-3-yl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032827-81-8 (S)-N-((3-(4-(4-(N-hydroxycarbamoyl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032897-90-7 (S,Z)-N-((3-(4-(4-(N'-methoxycarbamimidoyl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032827-80-7 (S,E)-methyl 3-(4-(2-fluoro-4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)phenyl)phenyl)acrylate 
• 1032827-82-9 (S)-N-((3-(4-(4-(carbamimidoyl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032827-76-1 N-(((S)-3-(4-(4-ethoxycarbonylphenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032827-79-4 (S,E)-N-((3-(4-(4-(2-nitrovinyl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 877875-99-5 (5S)-N-[3-(4'-cyano-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 

Relevant articles and documents

OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

NOVEL OXAZOLIDINONE DERIVATIVES, PROCESS FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to a novel oxazolidinone derivative, its prodrugs, hydrates, solvates, isomers, pharmaceutically permitted salts, and its preparation methods and pharmaceutical compositions containing the same. The oxazolidinone derivative and its pharmaceutically permitted salts according to the present invention have wide antimicrobial spectrum against resistant bacteria and low toxicity, and they show strong antibacterial effect against gram-positive and gram-negative pathogens. So, they can be used as good antibiotics.